B+
Bull case
30%
Probability
Target price
$96.00
Analysis reference price unavailable
Analysis 2026-09-19 · RankAlpha Sentiment Codex
GMED
Globus MedicalBNYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
Above-market US Spine growth, double-digit International Spine growth, gross-margin expansion and synergy realization support sustained earnings growth. Excelsius3D commercialization could strengthen ecosystem adoption, but its contribution is not yet quantified.
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.4.
What can break
Excelsius3D has regulatory clearance in Europe, but adoption timing, installed-base growth and revenue contribution remain unquantified. [#IR-2026-09-03]
Momentum
43
Value
65
Sentiment
51
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $84.00 · Bull $96.00 · Bear $61.00Analysis 2026-09-19; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-27 • Vendor: Data Vendor v1
Scores
As of 2026-10-27 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-19 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-27
Investment thesis
As of 2026-10-27
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-27. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $100.92
Why
Momentum43 · Δ7d -6.1
Value65 · Δ7d -0.4
Sentiment51 · Δ7d -10.5
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.4.
Contradictions & invalidation
- • Excelsius3D has regulatory clearance in Europe, but adoption timing, installed-base growth and revenue contribution remain unquantified. [#IR-2026-09-03]
- • Failure to deliver the reaffirmed 2026 revenue range or raised non-GAAP EPS guidance would weaken the operating-leverage thesis. [#SEC-8K-2026-08-06]
- • The thesis requires continued share gains and operating leverage after acquisitions.
Catalyst clock
2026-12-31
Full-year 2026 guidance delivery
Lead driver: Value · See fundamentals
Momentum
43
8% active weight
Current posture
7d trendSoftening
Δ7d
-6.1
Δ21d
+8.3
Value
65
47% active weight
Current posture
7d trendFlat
Δ7d
-0.4
Δ21d
-0.7
Sentiment
51
45% active weight
Current posture
7d trendSoftening
Δ7d
-10.5
Δ21d
-17.6
Why this grade
Composite grade B. Momentum 42.9 / Value 65.4 / Sentiment 51.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-19. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$84.00
Analysis reference price unavailable
Analysis 2026-09-19 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$61.00
Analysis reference price unavailable
Analysis 2026-09-19 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-27
Fundamentals (TTM)
As of 2026-10-27
Market Cap
$10.86B
Beta
1.06
Shares Out
134.26M
P/E (TTM)
29.2
P/S (TTM)
4.37
P/FCF (TTM)
21.25
Rev YoY
+5.9%
EPS YoY
-25.8%
Gross Margin
+64.9%
Op Margin
+21.5%
Net Debt
-$437.8M
Current Ratio
4.62
As of 2026-10-27 • Updated nightlySource: Internal modelMethods & Data